Therefore, development of incretin dual agonists such as the novel GCGR/GLP-1R dual agonist survodutide is an important step towards the more effective treatment of people with type 2 diabetes and obesity. Here, GCGR is linked to obesity due to melanocortin 4 receptor deficiency.